ActivistsInvestorsTrumpPoliticiansSerenityCitriniBurrySemianalysisSwingTradeArbitrageSearch

$ANNX:NASDAQ · ANNEXON INC

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.

More about this company

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Sector: health

Conviction from: NASDAQ

52-week range: 2.997.18

2 tracked filer(s) hold this · 0 opened, 2 added, 0 trimmed in 30-SEP-2026

Aggregate 13FScore 64 — mean of 2 scored holder(s) · buyers (new/add) avg 64. Higher = the smart money in this name has the better track record.

Filer13FScoreThis quarterSharesValue% of their book
Steve Cohen / Point7275Added +145%3,381,933$14,305,5770.0%
Louis Bacon / Moore52Added +6%452,545$1,914,2650.0%

Beyond 13F — activists, insiders, politicians & research

Insider open-market buys daily digest →

FiledInsiderRoleSharesValue
2026-05-29Satter Muneer Adirector613,497$3,319,019Form 4

Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.